WHO ICTRP trial
A Phase 1, Two-Stage, Dose-Escalation Study of BNC105P, a Novel Vascular…
ACTRN12607000520437 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12607000520437 |
|---|---|
| Public title | A Phase 1, Two-Stage, Dose-Escalation Study of BNC105P, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors |
| Scientific title | A Phase 1, Two-Stage, Dose-Escalation Study of BNC105P, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors |
| Primary sponsor | Bionomics Limited |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 1 |
| Countries | Australia |
| Conditions | Solid tumours; Solid tumours;Cancer - Other cancer types |
| Interventions | Two-stage dose escalation study involving intravenous administration of BNC105P on days 1 and 8 of a 21-day cycle. Stage 1 enrolls 1 patient per cohort and commences at 2.3 mg/m2 with 100% increments until significant toxicities are… |
| Registration date | Oct 10, 2007 |
| Target size | 30 |
| Secondary IDs | BNC105P.001 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: